Biolyst › RYTMRHYTHM PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study of Setmelanotide in Patients With Prader-Willi Syndrome on October 31, 2026. There are 5 upcoming events on record.
Cash runway is approximately 22.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 23 concluded trials, 100% reached completion rather than being terminated or withdrawn.
Track RYTM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RYTM in the tracker
Recent history
Date Event Type Phase
August 4, 2026
Quarterly results filed (8-K) Earnings
—
June 24, 2026
Open-Label Extension Study of Setmelanotide Trial Milestone
Phase 3
June 15, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
May 5, 2026
Quarterly results filed (8-K) Earnings
—
April 3, 2026
8-K filed: Leadership change, Reg FD disclosure Corporate
—
March 26, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
March 20, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
March 16, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
March 2, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
February 26, 2026
Quarterly results filed (8-K) Earnings
—
February 9, 2026
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Trial Milestone
Phase 2
January 9, 2026
Quarterly results filed (8-K) Earnings
—
December 22, 2025
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Trial Milestone
Phase 3
December 19, 2025
8-K filed: Leadership change Corporate
—
December 11, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
November 7, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
November 4, 2025
Quarterly results filed (8-K) Earnings
—
August 5, 2025
Quarterly results filed (8-K) Earnings
—
July 11, 2025
8-K filed: Other event Filing
—
July 9, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
May 7, 2025
Quarterly results filed (8-K) Earnings
—
March 18, 2025
A Trial of Setmelanotide in Acquired Hypothalamic Obesity Trial Milestone
Phase 3
January 9, 2025
Long Term Extension Trial of Setmelanotide Trial Milestone
Phase 2/Phase 3
October 19, 2023
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway Trial Milestone
Phase 3
September 18, 2023
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity Trial Milestone
Phase 3
August 4, 2023
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway Trial Milestone
Phase 2
June 28, 2022
Open-Label Study of Setmelanotide in Hypothalamic Obesity Trial Milestone
Phase 2
April 7, 2022
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants Trial Milestone
Phase 4
March 1, 2022
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity Trial Milestone
Phase 2
April 17, 2021
A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.